A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery

Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case,...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Yiqi, Ding, Zheng, Deng, Xianzhao, Guo, Bomin, Kang, Jie, Wu, Bo, Fan, Youben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188788/
https://www.ncbi.nlm.nih.gov/pubmed/32390940
http://dx.doi.org/10.3389/fendo.2020.00207
_version_ 1783527368063713280
author Niu, Yiqi
Ding, Zheng
Deng, Xianzhao
Guo, Bomin
Kang, Jie
Wu, Bo
Fan, Youben
author_facet Niu, Yiqi
Ding, Zheng
Deng, Xianzhao
Guo, Bomin
Kang, Jie
Wu, Bo
Fan, Youben
author_sort Niu, Yiqi
collection PubMed
description Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case, the (125)I seed implantation and vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor apatinib were co-applied to treat a 49-year-old woman with anaplastic thyroid cancer. After the patient began apatinib administration and underwent (125)I seed implantation twice, the tumor size shrank successfully. After a follow-up of 13 months since the initial diagnosis of anaplastic thyroid cancer, the patient survived with a stable disease pathology. In conclusion, this study supports (125)I seed implantation and apatinib as effective therapeutic alternatives for inoperable anaplastic thyroid cancer patients.
format Online
Article
Text
id pubmed-7188788
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71887882020-05-08 A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery Niu, Yiqi Ding, Zheng Deng, Xianzhao Guo, Bomin Kang, Jie Wu, Bo Fan, Youben Front Endocrinol (Lausanne) Endocrinology Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case, the (125)I seed implantation and vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor apatinib were co-applied to treat a 49-year-old woman with anaplastic thyroid cancer. After the patient began apatinib administration and underwent (125)I seed implantation twice, the tumor size shrank successfully. After a follow-up of 13 months since the initial diagnosis of anaplastic thyroid cancer, the patient survived with a stable disease pathology. In conclusion, this study supports (125)I seed implantation and apatinib as effective therapeutic alternatives for inoperable anaplastic thyroid cancer patients. Frontiers Media S.A. 2020-04-22 /pmc/articles/PMC7188788/ /pubmed/32390940 http://dx.doi.org/10.3389/fendo.2020.00207 Text en Copyright © 2020 Niu, Ding, Deng, Guo, Kang, Wu and Fan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Niu, Yiqi
Ding, Zheng
Deng, Xianzhao
Guo, Bomin
Kang, Jie
Wu, Bo
Fan, Youben
A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
title A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
title_full A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
title_fullStr A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
title_full_unstemmed A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
title_short A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
title_sort novel multimodal therapy for anaplastic thyroid carcinoma: (125)i seed implantation plus apatinib after surgery
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188788/
https://www.ncbi.nlm.nih.gov/pubmed/32390940
http://dx.doi.org/10.3389/fendo.2020.00207
work_keys_str_mv AT niuyiqi anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT dingzheng anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT dengxianzhao anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT guobomin anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT kangjie anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT wubo anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT fanyouben anovelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT niuyiqi novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT dingzheng novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT dengxianzhao novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT guobomin novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT kangjie novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT wubo novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery
AT fanyouben novelmultimodaltherapyforanaplasticthyroidcarcinoma125iseedimplantationplusapatinibaftersurgery

Ejemplares similares